---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-294328"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:32:21.617711+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology to cut 12% of workforce, close R&D sites; charges $30-40M

## Summary
- Workforce reduction of ~75 positions (12%) and closure of St. Louis and Portland R&D facilities in 2024.
- Estimated pre-tax charges of $30-40M, primarily facility-related; $3-4M cash expenditures. Annual savings at least $40M.
- Company to focus on chronic hepatitis delta/B programs and expand monoclonal antibody platform into autoimmune and oncology.
- Research to continue at San Francisco and Bellinzona sites.
- Cash, equivalents, and investments of $1.7B as of Q3 2023.

## SEC filing metadata
- accession: 0001193125-23-294328
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312523294328/0001193125-23-294328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312523294328/d643902d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-294328
- JSON: https://secwatch.observer/filing/0001193125-23-294328.json
- Plain text: https://secwatch.observer/filing/0001193125-23-294328.txt

## Key facts
- Restructurings & Charges
  Vir Biotechnology, Inc. announced a restructuring with charges of $30 million to $40 million affecting research and development facilities (approximately 12% of the workforce or 75 positions).
  - Type: restructuring
  - Charge: $30 million to $40 million
  - Affected area: research and development facilities
  - Headcount: approximately 12% of the workforce or 75 positions
  source text: continue at the Company’s sites in San Francisco, California and Bellinzona, Switzerland. As a result of these changes, the Company estimates that it will incur charges between $30 million to $40 million, primarily related to facility closures and to a lesser extent, employee severance costs. Of the total charges, the Company estimates that $3 million to $4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523294328/0001193125-23-294328-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.